Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward.
Nat Rev Clin Oncol., Feb;9(2):69-70 (2012)
Abandoning "TAP" as Treatment of Metastatic Endometrial Cancer: A Serious Example of the Consequences Resulting from the Failure To Adequately Define the Question Being Addressed in a Phase 3 Trial.
Curr Oncol Rep., Aug (2012)
Commentary: Implications of cancer managed as a "chronic illness".
Curr Oncol Rep., Apr;13(2):90-1 (2011)
Counterpoint: chemosensitivity assays for recurrent ovarian cancer.
J Natl Compr Canc Netw., Jan;9(1):121-4 (2011)
Information overload in oncology practice and its potential negative impact on the delivery of optimal patient care.
Curr Oncol Rep., Aug;13(4):249-51 (2011)
A Case Report of Hodgkin's Lymphoma in a Patient with Carcinosarcoma of the Bladder.
Case Rep Oncol., Sep;4(3):592-6 (2011)
Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic event.
Case Rep Oncol., Sep;4(3):490-1 (2011)
Synchronous presentation of a primary iliac lymph node plasmacytoma and a prostate adenocarcinoma.
Case Rep Oncol., May;4(2):311-4 (2011)
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Cancer Manag Res., 3:219-25 (2011)
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Gynecol. Oncol., Sep;122(3):473-8 (2011)
Elevated Serum CA-125 in a Patient with Follicular Lymphoma and a History of Ovarian Cancer.
Case Rep Oncol., 4(1):172-4 (2011)
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown.
Gynecol. Oncol., Aug;122(2):213-4 (2011)
Mucinous adenocarcinoma of the ovary.
Semin. Oncol., Aug;37(4):314-20 (2010)